Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Gladys Torres

Nurse Practitioner Miami, FL Nurse Practitioner

NPI 1396278867 CMS profile 10944099

1611 Nw 12Th Ave, Miami, FL 33136

Open in the dashboard

General payments

$7,869

396 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gladys Torres of Miami, FL is reported in the CMS Open Payments database as having received $7,869 across 396 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,346 59
2024 General $1,573 77
2023 General $1,576 70
2022 General $1,505 89
2021 General $1,869 101

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gladys Torres
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Gladys Torres were reported at $1,346. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Gladys Torres Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,869 $135 $40–$426 $132
2022 $1,505 $152 $48–$470 $149
2023 $1,576 $166 $54–$529 $160
2024 $1,573 $173 $55–$556 $164
2025 $1,346 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,319 67 payments
  2. Biohaven Pharmaceuticals, Inc. $786 51 payments
  3. Pfizer Inc. $707 34 payments
  4. SK Life Science, Inc. $643 27 payments
  5. ACADIA Pharmaceuticals Inc $605 34 payments
  6. Biohaven Pharmaceutical Holding Company Ltd. $482 33 payments
  7. Otsuka America Pharmaceutical, Inc. $414 19 payments
  8. Neurocrine Biosciences, Inc. $374 22 payments
  9. Eisai Inc. $360 16 payments
  10. UCB, Inc. $290 7 payments
  11. Other $1,890 86 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,788 391 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $70 3 payments
  3. Education $11 2 payments
Products named General payments · program years 2021–2025
  1. NURTEC ODT Primary Care $1,268 84 payments
  2. UBRELVY $1,076 53 payments
  3. QULIPTA $834 40 payments
  4. NURTEC ODT Pain $617 33 payments
  5. ZAVZPRET $610 30 payments
  6. NUPLAZID $506 29 payments
  7. REXULTI $414 19 payments
  8. INGREZZA $374 22 payments
  9. Ongentys $285 17 payments
  10. Leqembi $229 9 payments
  11. Other $2,699 118 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 42 drugs

Part D claims

2,441

Median for Nurse Practitioner: 389

Drug cost

$372,405

Median for Nurse Practitioner: $21,885

Branded share of claims

16.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rexulti Brexpiprazole Brand 67 $102,249
Copaxone Glatiramer Acetate Brand 15 $87,480
Nuplazid Pimavanserin Tartrate Brand 16 $78,086
Qulipta Atogepant Brand 23 $23,926
Rasagiline Mesylate Generic 92 $20,495
Nurtec Odt Rimegepant Sulfate Brand 14 $14,567
Neupro Rotigotine Brand 14 $11,552
Memantine Hcl Generic 350 $4,587
Lidocaine Generic 57 $4,431
Duloxetine Hcl Generic 242 $3,070

The 10 drugs with the highest cost, of 42 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $212
  • Lundbeck LLC $28
$240 67 —
UBRELVY
  • AbbVie, Inc. $185
$185 — —
QULIPTA
  • AbbVie, Inc. $177
$177 23 —
NUPLAZID
  • ACADIA Pharmaceuticals Inc $138
$138 16 —
Leqembi
  • Eisai Inc. $128
$128 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

396 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record